U.S. Diversified Financial Stock News

Intuitive Machines (LUNR) just posted a third consecutive up day after KeyBanc launched coverage with a buy rating and the company unveiled a new lunar infrastructure partnership with Leonardo and Telespazio. See our latest analysis for Intuitive Machines. Those bullish headlines land on top of a powerful near term run, with a 7 day share price return of about 64 percent and a roughly 86 percent 30 day share price gain, even though year to date share price performance and 1 year total...

ImmunityBio (IBRX) just added another data point to ANKTIVA’s story, with new Journal of Urology results showing the ANKTIVA plus BCG combo holding up at 12 and 36 months in difficult bladder cancer. See our latest analysis for ImmunityBio. Against that backdrop, ImmunityBio’s latest ANKTIVA milestones and fresh EMA traction come as the 90 day share price return of minus 13.01 percent and one year total shareholder return of minus 18.63 percent show that momentum is still rebuilding from a...

Wondering if Intuit is still worth buying after such a strong multi year run, or if most of the upside is already priced in? This breakdown will help you decide whether the current tag on the stock makes sense. Intuit's share price has climbed to around $674.83, with returns of 2.1% over the last week, 3.3% over the past month, 8.4% year to date, 5.3% over 1 year, and 82.8% and 85.4% over 3 and 5 years. This hints at both strong execution and rising expectations baked into the...

On December 16, 2025, Northwest Natural Holding Company announced two long-dated, fixed-rate callable mortgage bond offerings totaling US$200 million in principal, alongside planned 2026 leadership changes in its legal and compliance functions. The combination of fresh long-term funding and a transition to a new General Counsel and Chief Compliance Officer highlights how Northwest Natural is reshaping both its balance sheet and governance framework ahead of MardiLyn Saathoff’s April 2026...

Wondering if Ocular Therapeutix at around $12.71 is still a smart way to play biotech upside, or if most of the easy gains are already priced in? You are not alone. The stock is up 45.4% year to date and 52.6% over the last year, even after a recent 7.4% pullback this week and a more modest 5.0% gain over the last month. This builds on a 381.4% return over three years, despite being down 37.5% across five years. Recent moves have been driven by growing interest in Ocular Therapeutix's drug...

In recent months, UnitedHealth Group has responded to independent audits by outlining 23 operational reforms across its Medicare Advantage and Optum Rx pharmacy benefit operations, while also managing ongoing Department of Justice investigations into its billing practices. This combination of audit-driven changes and heightened regulatory attention is pushing the company to overhaul governance, automation, and transparency in ways that could materially reshape how it delivers and pays for...

Earlier this week, Italy’s Competition Authority ordered Meta Platforms to suspend contractual terms that kept rival AI chatbots off WhatsApp, requiring the company to allow competing services onto the messaging platform while an antitrust investigation continues. This intervention goes beyond technical integration, striking at how much control Meta can exert over AI services inside WhatsApp, a core pillar of its future messaging and AI monetization plans. We’ll now examine how Italy’s move...

In recent months, Rigetti Computing has drawn fresh attention as quantum computing enthusiasm accelerated, supported by new commercial orders for its Novera systems, expanded partnerships, and growing interest from institutional investors and Wall Street analysts. What stands out is how Rigetti’s vertically integrated superconducting-qubit platform and clear hardware roadmap are starting to translate into early real-world deployments and ecosystem collaborations, rather than remaining...

If you are wondering whether Expeditors International of Washington is still worth considering after its big run, or if the easy money has already been made, this breakdown is designed to help you decide with less guesswork. The stock has climbed 1.2% over the last week, 5.1% over the past month, and is now up 37.8% year to date and 38.0% over the last year, building on gains of 50.8% over 3 years and 69.7% over 5 years. Recent attention around global trade routes, freight demand stability,...

On 12 December 2025, UBS analyst Danielle Antalffy initiated coverage of PROCEPT BioRobotics with a bullish view, highlighting expectations for expanding revenue, improving gross margins, and cost efficiencies that could support profitability by 2027. This upbeat initiation adds to already optimistic analyst sentiment around PROCEPT’s urology-focused surgical robotics platform, with no Sell ratings and most covering analysts expecting meaningful growth in its Aquablation-based...

In recent days, Bloom Energy has been in focus as its solid oxide fuel cells gain traction as on-site power solutions for AI data centers, supported by record quarterly revenue, positive free cash flow, and a new US$600 million revolving credit facility led by Wells Fargo to enhance liquidity. At the same time, major partnerships with operators like Oracle and Brookfield and plans to double manufacturing capacity by 2026 underscore how tightly Bloom’s growth prospects are now tied to the...

If you are wondering whether Tesla is still a buy at today’s price, you are not alone. This article is going to walk through what the numbers say about its current valuation. Over the last month the stock has climbed 16.2%, adding to a 28.0% gain year to date and a 330.7% return over three years. This naturally raises questions about how much upside is really left. Recent headlines have focused on Tesla’s push to deepen its AI and autonomous driving capabilities, regulatory approvals for...

MP Materials (MP) is back in focus after a Morgan Stanley upgrade highlighted its role in the rare earths supply chain, even as recent CEO and CFO share sales contrast with growing institutional buying. See our latest analysis for MP Materials. The latest Morgan Stanley upgrade comes after a choppy stretch, with a 1 year to date share price return of 232.76 percent but a 90 day share price return of negative 29.29 percent. At the same time, the 3 year total shareholder return of 130.42...

On Holding (NYSE:ONON) has quietly staged a comeback, with the stock up roughly 14% over the past month, even as year to date performance and 1 year returns remain in negative territory. See our latest analysis for On Holding. The recent 30 day share price return of about 14% suggests momentum is rebuilding after a softer patch, even though year to date share price performance and the 1 year total shareholder return are still in the red, while the three year total shareholder return remains...

Recent Performance Puts Nasdaq in Focus Nasdaq (NDAQ) has been quietly climbing, with the stock up about 12% over the past month and 27% year to date, drawing fresh attention to how its evolving, tech-driven model is being valued. See our latest analysis for Nasdaq. With the share price now around $98.64, supported by a strong year to date share price return and robust multi year total shareholder returns, momentum looks to be building as investors increasingly back Nasdaq’s tech heavy,...

Microsoft (MSFT) has quietly drifted higher recently, with the stock up about 3% over the past month and roughly 17% year to date, even as gains cooled in the past 3 months. See our latest analysis for Microsoft. That steady climb comes after a brief cooling period, with the current share price at $488.02 and a solid year to date share price return suggesting momentum is consolidating rather than collapsing, backed by very strong multi year total shareholder returns. If Microsoft has you...

Medpace Holdings (MEDP) has quietly become one of the stronger long term performers in clinical research, with the stock up around 67% over the past year despite a recent pullback this month. See our latest analysis for Medpace Holdings. The recent pullback, including a roughly 7.5% 1 month share price return decline, comes after a powerful run in which the share price has climbed about 71% year to date and contributed to a three year total shareholder return of 174%. This suggests momentum...

Whether you see Pony AI as a hidden bargain or already priced for perfection, this piece will walk through what the current share price really implies. The stock has been lively lately, climbing 10.7% over the last week, 24.5% over the past month, and 20.4% over the last year, even though it is only up 3.2% year to date from its last close at $15.68. Investors have been reacting to a steady drumbeat of headlines around autonomous driving partnerships and regulatory milestones in key U.S. and...

If you are wondering whether ServiceNow is starting to look like a bargain or still priced for perfection, you are in the right place. Despite a tough stretch recently, with the stock down around 2.5% over the last week, 6.5% over the last month, and 27.6% year to date, long term holders are still sitting on gains of about 103% over three years. Recent headlines have focused on ServiceNow continuing to win large enterprise deals and deepening partnerships across its platform. This reinforces...

Hubbell (HUBB) has been quietly rewarding patient shareholders, with the stock up about 9% over the past 3 months and more than doubling over three years, powered by steady earnings growth. See our latest analysis for Hubbell. At around $456 per share, Hubbell’s recent 7 day share price return of just over 6% builds on a strong multi year total shareholder return. This suggests investors are steadily pricing in its consistent earnings execution rather than a one off catalyst. If Hubbell’s...

Earlier in December 2025, Apollo Global Management signaled a risk-off posture by hoarding cash, cutting exposure to CLOs and AI-related loans, and warning about systemic vulnerabilities in private credit and offshore insurance structures. This shift highlights how a large alternative asset manager can both reposition its own balance sheet and publicly flag potential fault lines in insurance-linked and tech-oriented credit markets. We’ll now examine how Apollo’s decision to prioritize...

Wondering if Sandisk is still worth buying after its massive run, or if the smart move now is to wait for a better entry point? Let us unpack whether the current price still stacks up to the company’s fundamentals. The stock has surged 20.9% over the last week, 10.2% over the past month, and an eye catching 594.7% year to date, putting it firmly on many investors’ watchlists and significantly changing how the market is pricing its future. Recent headlines have focused on Sandisk’s...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

As the U.S. stock market continues to reach new heights with the S&P 500 hitting an all-time high, investors are keenly observing opportunities that might be trading below their estimated value. In such a vibrant market environment, identifying undervalued stocks requires careful analysis of fundamentals and market positioning, making it essential to consider companies like Atour Lifestyle Holdings that may offer potential value at current prices.